Comparison of effectiveness and efficacy of amoxicillin for acute uncomplicated LRTI in primary care
| Outcome | Effectiveness* | Effectiveness for whom adherence data were also available† | Efficacy per 10% increase in adherence† | Maximum efficacy (100% adherence)† |
|---|---|---|---|---|
| Adjusted between-group mean difference in symptom severity between days 2 and 4 postrandomisation | −0.07 (−0.15 to 0.01) | −0.07 (−0.15 to 0.01) | −0.008 (−0.017 to 0.001) | −0.08 (−0.17 to 0.01) |
| OR for developing new or worsening symptoms in the 4 weeks postrandomisation | 0.79 (0.63 to 0.99) | 0.81 (0.64 to 1.03) | 0.978 (0.960 to 0.998) | 0.81 (0.66 to 0.98) |
| OR for reporting non-respiratory symptoms/side effects in the 4 weeks postrandomisation | 1.28 (1.03 to 1.59) | 1.28 (1.04 to 1.59) | 1.028 (1.011 to 1.046) | 1.32 (1.12 to 1.57) |
*Analysis based on 1789, 2027 and 1727 participants for the symptom severity, new symptoms and side effect outcomes, respectively.
†Analysis based on 1787, 1923 and 1725 participants for the symptom severity, new symptoms and side effect outcomes, respectively.
LRTI, lower-respiratory-tract infection.